Think about mental health and the impact of our INVEGA portfolio, SPRAVATO and the potential of ... providing strategic near and long-term growth catalyst for Johnson & Johnson.

Think about mental health and the impact of our Invega portfolio, Spravato, and the potential ... providing strategic near- and long-term growth catalysts for Johnson & Johnson.

However, if its focus is more on the near-term, Wall Street may argue it ... Also mentioned were depression med Spravato - $1bn revenues in 2024, up 56%, Tremfya, expected to be a long-term ...

It has been used as a party drug for decades but is an “approved medical product as an injectable, short-acting anesthetic for use in humans and animals and as a nasal spray (Spravato ...

She told me that she didn’t know it was possible to feel this good, saying that it wasn’t until she took Spravato that she realized she didn’t have to walk in the fog anymore. Full Interview Summary: ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA has blessed the nasal spray to be used as a monotherapy for major ...

Please provide your email address to receive an email when new articles are posted on . Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.